Clinical Trial Update: Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating re-induction with carfilzomib, lenalidomide, and dexamethasone followed by a second autologous stem cell transplant in multiple myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Samsung Medical Center | Conditions: Multiple Myeloma | Phase 2 | Status: UNKNOWN